The I4RON-HF study, intravenous iron isomaltoside for inpatients veRsus outpatient Asians with heart failure

Abstract

Iron deficiency (ID) impacts ~50% of heart failure (HF) patients and is a risk factor and strong predictor for death and mortality with or without anaemia. Oral iron appears to be ineffective whilst intravenous iron (IV-iron) has proven to be efficacious however data is primarily from a Caucasian population despite ID being more prevalent amongst Asians. The I4RON-HF study assesses efficacy of high-dose IV-iron versus oral iron in stable outpatients and inpatients recovering from episodes of decompensated HF.